Depo Provera Global Settlement 2026: What It Means for Claims

Updated: July 16, 2026 | Review: Legal Lawsuit Editorial Team | Sources Used: peer-reviewed BMJ research, FDA drug safety records, and federal MDL court filings.

On June 15, 2026, a global Depo-Provera settlement agreement in principle was announced — the biggest development since the litigation began. If you or someone you love received Depo-Provera injections and was later diagnosed with a meningioma, this news could directly affect your right to compensation. Here is what has been confirmed about the agreement and what you should do now to protect your claim.

The Depo-Provera Global Settlement Agreement Explained

On June 15, 2026, U.S. District Judge M. Casey Rodgers entered Pretrial Order No. 30A confirming that Plaintiffs’ Lead Counsel Christopher Seeger (Seeger Weiss) and defendants Pfizer Inc., Pharmacia LLC, and Pharmacia & Upjohn Co. LLC had reached a global agreement in principle to resolve thousands of meningioma claims pending in MDL No. 3140. It is the first major resolution framework in litigation that grew from 78 cases in March 2025 to over 5,500 by June 2026.

Put simply, a Depo-Provera settlement is a negotiated deal between Pfizer and people who claim that long-term use of the shot caused meningiomas — usually benign but potentially serious tumors of the membranes around the brain or spinal cord. A global agreement aims to resolve thousands of claims without separate jury trials.

What was confirmed as of June 19, 2026:

• The court’s own order confirms a global agreement in principle.
• The Rule 702/Daubert hearing on general causation was moved from June 24–25 to July 27, 2026, in Pensacola, Florida, while the details are completed.
• Bellwether trials that had been set for December 2026 were put on hold.
• Judge Rodgers noted the agreement will not include every MDL claimant, so some cases will continue to be litigated.

Still unconfirmed: Official payout amounts, eligibility rules, the claims process, payment tiers, and deadlines had not been released, and the parties were still “memorializing the details.” Don’t treat any figure you see elsewhere as an official Pfizer offer.

What the Depo-Provera Lawsuit Claims

Depo-Provera (medroxyprogesterone acetate) is Pfizer’s injectable contraceptive, used by millions of women for decades. Plaintiffs in the Depo-Provera lawsuit claim that long-term use substantially raises the risk of meningioma, a tumor of the brain or spine that can require major surgery and radiation and cause lasting neurological damage.

Two peer-reviewed studies strengthened the scientific case considerably. A 2024 study in the British Medical Journal (BMJ) reported a 5.6-fold higher risk of meningioma among long-term users, and a 2025 JAMA Neurology study of roughly 10 million women found a 2.43-fold higher risk. Those results put real pressure on Pfizer’s defense and are widely seen as speeding up settlement talks.

In December 2025, the U.S. Food and Drug Administration (FDA) had Pfizer add an explicit meningioma warning to the Depo-Provera label, a step plaintiffs’ lawyers point to as a key reason the parties moved toward settlement. Overseen by Judge Rodgers in the Northern District of Florida, MDL No. 3140 has been among the fastest-growing drug MDLs nationwide, adding about 1,831 cases in the 30 days before the announcement, according to JPML filings.

What Is Known About Depo-Provera Settlement Value

Because the official terms have not been released, any dollar amount you see online is guesswork drawn from attorney commentary and other MDLs. Here is a straightforward summary:

Confirmed: A global agreement exists, but neither Pfizer nor the court has announced any payout figures.

What will likely matter: Without official terms, published dollar predictions are speculation. Based on how similar drug settlements are usually structured, individual payments are expected to depend on the tumor’s severity, the treatment required (such as surgery or radiation), lasting disability, and how long the shot was used.

A past reference point: Pfizer earlier settled a Canadian Depo-Provera class action over bone density loss, a different injury, for about $2 million in total. That shows Pfizer has settled Depo-Provera claims before, but it says nothing about what meningioma claims may be worth.

To learn more about what affects individual claim value in this MDL, see if you may qualify for a similar recovery in our detailed settlement guide.

Who May Be Covered by the Depo-Provera Settlement?

Official eligibility rules have not been published yet. Based on how settlements like this are usually set up, attorneys reviewing claims now focus on these factors:

• A meningioma diagnosis — A confirmed diagnosis of meningioma of the brain or spinal cord is the core injury in this litigation.
• A history of Depo-Provera shots — Documented use, often for a year or longer, although shorter use may still be reviewed.
• Medical and pharmacy records — Records tying your Depo-Provera use to your diagnosis are usually needed.
• Filing deadlines — Deadlines commonly run 2–3 years from diagnosis or discovery, and with settlement activity underway, prompt action matters.
• Wrongful death claims — Relatives may qualify if a family member died from a meningioma linked to Depo-Provera.

Judge Rodgers has said the global agreement will not cover every claimant in the MDL. Talking with an attorney now is the best way to learn where your claim stands and whether it falls inside or outside the settlement. You may also qualify for other active mass tort lawsuits Legal Lawsuit follows nationwide.

What Determines the Value of a Depo-Provera Settlement Claim?

Each claim’s value will depend on a mix of medical, financial, and legal factors. No official tiers have been released, but attorneys weigh several key elements when reviewing cases. For a personalized look, estimate what your case could be worth now using our settlement calculator.

The tumor’s severity is among the biggest factors. A large meningioma that required emergency surgery, left lasting cognitive or neurological damage, or came back after treatment is likely to be valued much higher. The extent of treatment — surgery, radiation, hospital stays, and specialist follow-up — affects both economic damages and the overall strength of the claim.

Lost income and reduced earning ability also weigh heavily, especially for people diagnosed during their prime working years, since neurological effects from the tumor or its treatment can permanently limit the ability to work. How long Depo-Provera was used matters as well: research ties extended use, often three years or more, to the greatest increase in risk, which can strengthen causation and claim value.

Next Steps in the Depo-Provera MDL

In a mass tort this large, moving from an agreement in principle to actual payments usually takes months. The parties must put the settlement into a formal written agreement that sets payment tiers, eligibility rules, a claims administration process, and filing deadlines, which can take weeks or months after the first announcement.

Daubert hearing set for July 27, 2026: The Rule 702/Daubert hearing on general causation was moved from June 24–25 to July 27, 2026, in Pensacola, Florida, while the agreement is completed. If a final settlement comes first, the hearing may be canceled; if finalizing takes longer, the hearing will go forward and could shape any remaining litigation.

Claims not covered by the settlement: Judge Rodgers has been clear that the global framework will not resolve every claim. Cases outside it, whether because of injury type, timing, or other reasons, will stay in active litigation and move toward bellwether trials once the settlement picture becomes clearer.

Don’t wait for deadlines to be announced: Settlement programs often set early filing or registration deadlines, and claimants who have counsel before the rules are finalized are usually better positioned. Filing deadlines also keep running during negotiations. If you have a meningioma diagnosis tied to Depo-Provera, reaching out to an attorney now, even before official terms are released, is the most important step you can take.

Common Questions

Related Articles